Phase I/II randomized double-blind study of DJ-01 for moderate to severe glabellar lines

Phase 2, randomised, double-blind trial of DJ-01 in glabellar furrowing (12 arms), sponsored by Plastic Surgery Hospital of Chinese Academy of Medical Sciences. Primary endpoints: Incidence and severity of adverse events and serious adverse events; injection-site adverse events; dose-limiting toxicity and Investigator-assessed responder rate at maximum frown by ILA-FWS. Planned start May 2025; status: not yet recruiting.